Study S002016

Central Effects of Endogenous Glucagon Like Peptide-1 (GLP-1) and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01363609
Acronym: LIBRA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 50
Start: 2011-10
Primary completion: 2015-01
Lead sponsor: Amsterdam UMC, location VUmc
Conditions: Obesity; Type 2 Diabetes
Interventions: DRUG:Liraglutide treatment 12 weeks; DRUG:insulin glargine treatment; DRUG:GLP-1 receptor antagonist
Results posted: FALSE

Registered primary outcomes

food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%) [approximately 3 years]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0028201	Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. ten Kulve JS, Diabetologia	2015	Randomized trial	PMID 26385462 DOI	cites ClinicalTrials.gov:NCT01363609; registry reference DERIVED:26385462